A股异动丨泰格医药发盈喜股价冲击涨停创历史新高
格隆汇6月26日丨泰格医药(300347.SZ)今日强势上涨,盘中冲击涨停股价创新高。现涨8.58%,报73.92元,暂成交3.11亿元,最新总市值370.68亿元。

6月25日,泰格医药(300347.SZ)发布2019年半年度业绩预告,泰格医药预计2019年上半年盈利3.28亿元至3.72亿元,较上年同期增长50%-70%。报告期内,公司主营业务持续增长,预计2019年半年度营业收入和归属于上市公司股东的净利润均较上年同期有所增长。
此前,卫健委、CDE相继发布政策鼓励仿制专利即将到期产品、持续推进仿制药一致性评价工作、NSCLC临床试验指导原则鼓励肺癌领域新药研发。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.